Condition: Type 2 Diabetes · Sponsor: The University of Texas Health Science Center at San Antonio
To examine whether the empagliflozin-induced stimulation of EGP, lipolysis, and ketone production in T2D individuals can be blocked by pioglitazone (which has direct hepatic and adipose tissue effects).
This description comes directly from the study's public registry record.
Ralph DeFronzo, MD · 210-567-6691 · defronzo@uthscsa.edu
Aurora Merovci, MD · 210-567-6691 · merovci@uthscsa.edu
Always discuss trial participation with your own doctor first.
| Texas Diabetes Institute/UH | San Antonio, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07053319